In the last trading session, 1.32 million Nektar Therapeutics (NASDAQ:NKTR) shares changed hands as the company’s beta touched 0.60. With the company’s per share price at $1.41 changed hands at -$0.04 or -2.76% during last session, the market valuation stood at $259.55M. NKTR’s last price was a discount, traded about -36.88% off its 52-week high of $1.93. The share price had its 52-week low at $0.41, which suggests the last value was 70.92% up since then. When we look at Nektar Therapeutics’s average trading volume, we note the 10-day average is 1.51 million shares, with the 3-month average coming to 1.03 million.

Analysts gave the Nektar Therapeutics (NKTR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NKTR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Nektar Therapeutics’s EPS for the current quarter is expected to be -0.21.

Nektar Therapeutics (NASDAQ:NKTR) trade information

Instantly NKTR was in red as seen at the end of in last trading. With action 3.68%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 149.56%, with the 5-day performance at 3.68% in the green. However, in the 30-day time frame, Nektar Therapeutics (NASDAQ:NKTR) is 11.02% up. Looking at the short shares, we see there were 7.31 million shares sold at short interest cover period of 8.5 days.

The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 92.38% from its current market value. According to analyst projections, NKTR’s forecast low is 6 with 24 as the target high. To hit the forecast high, the stock’s price needs a -1602.13% plunge from its current level, while the stock would need to soar -325.53% for it to hit the projected low.

Nektar Therapeutics (NKTR) estimates and forecasts

Data shows that the Nektar Therapeutics share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 13.71% over the past 6 months, a 41.38% in annual growth rate that is considerably higher than the industry average of 17.50%. Year-over-year growth is forecast to reach -11.20% down from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 18.28M. 6 analysts are of the opinion that Nektar Therapeutics’s revenue for the current quarter will be 17.5M. The company’s revenue for the corresponding quarters a year ago was 24.14M and 23.89M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -24.30%. The estimates for the next quarter sales put growth at -26.70%.

The 2024 estimates are for Nektar Therapeutics earnings to increase by 45.11%, but the outlook for the next 5-year period is at -7.30% per year.

NKTR Dividends

Nektar Therapeutics is expected to release its next quarterly earnings report in November.

Nektar Therapeutics (NASDAQ:NKTR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.06% of Nektar Therapeutics shares while 74.01% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 74.80%. There are 74.01% institutions holding the Nektar Therapeutics stock share, with DEEP TRACK CAPITAL, LP the top institutional holder. As of 2024-06-30, the company held 9.1789% of the shares, roughly 17.88 million NKTR shares worth $22.17 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30.